14 Dec 2009 17:23
| Press Release | 14 December 2009 |
Plethora Solutions Holdings plc
("Plethora" or "the Company")
Holdings in the Company
Plethora Solutions Holdings plc (AIM:PLE), the UK based specialty pharmaceutical company, was notified on 10 December 2009 that subsequent to the placing of new ordinary shares by the Company (as announced on 18 November 2009), that:
Invesco Limited is now interested in 4,600,000 ordinary shares (representing approximately 10.96% of the Company's total issued share capital); and
Invesco English & International Trust is now interested in 1,584,704 ordinary shares (representing approximately 3.77% of the Company's total issued share capital).
For further information:
| Plethora Solutions | |
| Steven Powell / Ronald Openshaw | Tel: +44 (0) 20 3077 5400 |
| www.plethorasolutions.co.uk |
| FinnCap | |
| Geoff Nash / Henrik Persson, Corporate Finance | Tel: +44 (0) 20 7600 1658 |
| Simon Starr, Corporate Broking | www.finncap.com |
Media enquiries:
| Hansard Group | |
| John Bick / Kirsty Corcoran | Tel: +44 (0) 20 7245 1100 |
| www.hansardgroup.co.uk |
About Plethora:
Plethora is focused on the development and marketing of products for the treatment of urological disorders. The Company has products in clinical development for the treatment of overactive bladder (PSD506), stress urinary incontinence (PSD503), interstitial cystitis (PSD597), gynaecological pain (PSD508), erectile dysfunction (PSD510) and premature ejaculation (PSD502). Plethora's subsidiary, The Urology Company Limited, was established in 2009 to market and distribute a range of therapeutic products for the treatment of urology, andrology and obstetric conditions. The Company is headquartered in the UK and is listed on the London Stock Exchange.
Further information is available at www.plethorasolutions.co.uk